NP-59 Adrenal Scintigraphy as an Imaging Biomarker to Predict Mutation in Primary Aldosteronism Patients.

PURPOSE

Somatic mutation occurs in half of unilateral primary aldosteronism (PA) and is associated with more severe phenotype. Mutation status can only be identified by tissue sample from adrenalectomy. NP-59 adrenal scintigraphy is a noninvasive functional study for disease activity assessment. This study aimed to evaluate the predictive value of NP-59 adrenal scintigraphy in somatic mutation among PA patients who received adrenalectomy.

METHODS

Sixty-two PA patients who had NP-59 adrenal scintigraphy before adrenalectomy with available mutation status were included. Two semiquantitative parameters, adrenal to liver ratio (ALR) and lesion to contralateral ratio of bilateral adrenal glands (CON) derived from NP-59 adrenal scintigraphy, of mutated and wild-type patients were compared. Cutoff values calculated by receiver-operating characteristic (ROC) analysis were used as a predictor of mutation.

RESULTS

Twenty patients had mutation and 42 patients were wild type. Patients harboring mutation had both higher ALR and CON (p = 0.0031 and 0.0833, respectively) than wild-type patients. With ALR and CON cutoff of 2.10 and 1.95, the sensitivity and specificity to predict mutation were 85%, 57% and 45%, 93%, respectively. Among 20 patients with mutation, 16 showed G151R point mutation (- G151R) and 4 showed L168R point mutation (-L168R), which former one had significantly lower ALR (p=0.0471).

CONCLUSION

PA patients harboring somatic mutation had significantly higher NP-59 uptake regarding to ALR and CON than those without mutation. APAs with L168R point mutation showed significantly higher ALR than those with -G151R point mutation.